<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background: Epigenetic deregulation of gene expression is a newly recognized mechanism that leads to <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> such as <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>DNA methylation is one of the most commonly occurring epigenetic events </plain></SENT>
<SENT sid="2" pm="."><plain>Objective/methods: The rationale and use of hypomethylation agents in adult <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> are discussed </plain></SENT>
<SENT sid="3" pm="."><plain>Data in this review came from the published literature </plain></SENT>
<SENT sid="4" pm="."><plain>Results/conclusion: In <z:hpo ids='HP_0001909'>leukemias</z:hpo>, alterations in DNA methylation are characterized by the hypermethylation of several genes </plain></SENT>
<SENT sid="5" pm="."><plain>Hypermethylation represses transcription of the promoter regions of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes leading to gene silencing </plain></SENT>
<SENT sid="6" pm="."><plain>This change is reversible making it an important therapeutic target </plain></SENT>
<SENT sid="7" pm="."><plain>Drugs such as methyltranferase inhibitors including <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> and <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi>, and <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitors are being used in the treatment of these <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>